Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1988 1
1989 2
1990 1
1991 3
1992 3
1993 3
1994 1
1995 4
1997 4
1998 6
1999 2
2000 2
2001 5
2002 5
2003 4
2004 7
2005 11
2006 4
2007 10
2008 6
2009 6
2010 16
2011 26
2012 16
2013 13
2014 14
2015 12
2016 18
2017 27
2018 24
2019 22
2020 32
2021 23
2022 31
2023 25
2024 32
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

375 results

Results by year

Filters applied: . Clear all
Page 1
Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatments.
Gougis P, Hilmi M, Geraud A, Mir O, Funck-Brentano C. Gougis P, et al. Crit Rev Oncol Hematol. 2021 Oct;166:103342. doi: 10.1016/j.critrevonc.2021.103342. Epub 2021 Apr 28. Crit Rev Oncol Hematol. 2021. PMID: 33930533 Free article. Review.
Herbs, food and dietary supplements (HFDS), can interact significantly with anticancer drug treatments via cytochrome p450 isoforms (CYP) CYP3A4, CYP2D6, CYP1A2, and CYP2C8. The objective of this review was to assess the influence of HFDS compounds on these cytochro …
Herbs, food and dietary supplements (HFDS), can interact significantly with anticancer drug treatments via cytochrome p450 isoforms ( …
CYP2C8 regulated by GAS5/miR-382-3p exerts anti-cancerous properties in liver cancer.
Li K, Chen Y. Li K, et al. Cancer Biol Ther. 2020 Dec 1;21(12):1145-1153. doi: 10.1080/15384047.2020.1840886. Epub 2020 Nov 12. Cancer Biol Ther. 2020. PMID: 33180658 Free PMC article.
A cornucopia of literatures has characterized the involvement of a host of functional molecules in liver cancer. Herein, according to online datasets, we found that cytochrome P450 family 2 subfamily C member 8 (CYP2C8) was downregulated in liver cancer …
A cornucopia of literatures has characterized the involvement of a host of functional molecules in liver cancer. Herein, according to …
The impact of genetic variants in the CYP2C8 gene on bladder cancer susceptibility.
Qu W, Zhang F, Cheng Y, Li J, Zhou J. Qu W, et al. Front Endocrinol (Lausanne). 2022 Sep 28;13:989030. doi: 10.3389/fendo.2022.989030. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36246885 Free PMC article.
BACKGROUND: Bladder cancer is the most common leading cause of mortality around the world. Previous studies have indicated that genetic factors are significantly associated with bladder cancer progression-for instance, the CYP2C8 gene is involved in bladder …
BACKGROUND: Bladder cancer is the most common leading cause of mortality around the world. Previous studies have indicated that genet …
Lovastatin enhances chemosensitivity of paclitaxel-resistant prostate cancer cells through inhibition of CYP2C8.
Li Y, Chen S, Zhu J, Zheng C, Wu M, Xue L, He G, Fu S, Deng X. Li Y, et al. Biochem Biophys Res Commun. 2022 Jan 22;589:85-91. doi: 10.1016/j.bbrc.2021.12.007. Epub 2021 Dec 3. Biochem Biophys Res Commun. 2022. PMID: 34896780
Quantitative RT-PCR showed that the combination of paclitaxel and LV could significantly reduce the expression of CYP2C8, an important drug-metabolizing enzyme. Bioinformatics analysis from the TCGA database showed that CYP2C8 expression was negatively correlated wi …
Quantitative RT-PCR showed that the combination of paclitaxel and LV could significantly reduce the expression of CYP2C8, an importan …
Rottlerin renders a selective and highly potent CYP2C8 inhibition to impede EET formation for implication in cancer therapy.
Manhas D, Bhatt S, Rai G, Kumar V, Bharti S, Dhiman S, Jain SK, Sharma DK, Ojha PK, Gandhi SG, Goswami A, Nandi U. Manhas D, et al. Chem Biol Interact. 2023 Aug 1;380:110524. doi: 10.1016/j.cbi.2023.110524. Epub 2023 May 3. Chem Biol Interact. 2023. PMID: 37146929
CYP2C8 converts arachidonic acid to epoxyeicosatrienoic acids (EETs) that cause cancer progression. ...Rottlerin substantially hindered the EET formation in HLM. Overall results of rottlerin on CYP2C8 inhibition and EET formation insinuate further exploration …
CYP2C8 converts arachidonic acid to epoxyeicosatrienoic acids (EETs) that cause cancer progression. ...Rottlerin substantially …
Polymorphisms in Phase I (CYP450) Genes CYP1A1 (rs4646421), CYP1B1 (rs1056836), CYP19A1 (rs749292) and CYP2C8 (rs1058930) and Their Relation to Risk of Breast Cancer: A Case-Control Study in Mazandaran Province in North of Iran.
Golmohammadzadeh G, Mohammadpour A, Ahangar N, Shokrzadeh M. Golmohammadzadeh G, et al. Open Access Maced J Med Sci. 2019 Aug 10;7(15):2488-2496. doi: 10.3889/oamjms.2019.667. eCollection 2019 Aug 15. Open Access Maced J Med Sci. 2019. PMID: 31666853 Free PMC article.
Based on using a logistic regression model in two normalized and age-adjusted models to finding relationship between the genotypes of each gene and breast cancer risk, it was determined that in the CYP2C8 genotype, those who have the CG allele have a 7.74 degree inc …
Based on using a logistic regression model in two normalized and age-adjusted models to finding relationship between the genotypes of each g …
Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.
Nthontho KC, Ndlovu AK, Sharma K, Kasvosve I, Hertz DL, Paganotti GM. Nthontho KC, et al. Pharmgenomics Pers Med. 2022 Jun 21;15:613-652. doi: 10.2147/PGPM.S308531. eCollection 2022. Pharmgenomics Pers Med. 2022. PMID: 35761855 Free PMC article. Review.
Breast cancer is the most frequent cause of cancer death in low- and middle-income countries, in particular among sub-Saharan African women, where response to available anticancer treatment therapy is often limited by the recurrent breast tumours and metastasis, ult …
Breast cancer is the most frequent cause of cancer death in low- and middle-income countries, in particular among sub-Saharan …
Unintentional combining enzalutamide with a moderate CYP2C8 inhibitor in a patient with metastatic castration-resistant prostate cancer: a case report.
Verhulst SH, Boerrigter E, Ras S, van Erp NP, Hamberg P. Verhulst SH, et al. Cancer Chemother Pharmacol. 2022 Apr;89(4):539-542. doi: 10.1007/s00280-021-04379-y. Epub 2022 Jan 21. Cancer Chemother Pharmacol. 2022. PMID: 35059789
BACKGROUND: Enzalutamide, registered for the treatment of metastatic castration-resistant prostate cancer (mCRPC), is an inducer of multiple CYP-enzymes. Enzalutamide itself is mainly converted by CYP2C8 to the active metabolite N-desmethylenzalutamide (NDME). ...Th …
BACKGROUND: Enzalutamide, registered for the treatment of metastatic castration-resistant prostate cancer (mCRPC), is an inducer of m …
Buprenorphine in cancer pain.
Davis MP. Davis MP. Support Care Cancer. 2005 Nov;13(11):878-87. doi: 10.1007/s00520-005-0849-9. Epub 2005 Jul 12. Support Care Cancer. 2005. PMID: 16010532 Review.
Buprenorphine can be given by several routes. Metabolism is through CYP3A4 and CYP2C8 and by conjugases. Constipation and sexual dysfunction appear to be less with buprenorphine than with other opioids. ...Buprenorphine has been used extensively to control cancer pa …
Buprenorphine can be given by several routes. Metabolism is through CYP3A4 and CYP2C8 and by conjugases. Constipation and sexual dysf …
Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
Guijosa A, Freyria A, Espinosa-Fernandez JR, Estrada-Mena FJ, Armenta-Quiroga AS, Ortega-Treviño MF, Catalán R, Antonio-Aguirre B, Villarreal-Garza C, Perez-Ortiz AC. Guijosa A, et al. Clin Transl Sci. 2022 Oct;15(10):2403-2436. doi: 10.1111/cts.13370. Epub 2022 Aug 17. Clin Transl Sci. 2022. PMID: 35892315 Free PMC article.
Taxane-based chemotherapy regimens are used as first-line treatment for breast cancer. Neurotoxicity, mainly taxane-induced peripheral neuropathy (TIPN), remains the most important dose-limiting adverse event. ...For this reason, we systematically reviewed observational st …
Taxane-based chemotherapy regimens are used as first-line treatment for breast cancer. Neurotoxicity, mainly taxane-induced periphera …
375 results